# Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors

> **NCT05976906** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)

## Key facts

- **NCT ID:** NCT05976906
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-23
- **Primary completion:** 2025-05
- **Final completion:** 2025-09
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05976906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05976906, "Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05976906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*